Article Text

Download PDFPDF

OP-011 Clinical outcomes of pediatric growth hormone deficiency treated with weekly somapacitan: insights from Saudi Arabia
  1. Abdulmoein Al-Agha
  1. King Abdulaziz University, Faculty of Medicine


Aim Disparities in the regional prevalence of childhood growth hormone deficiency (GHD) in Saudi Arabia are evident, with the highest incidence in the Northern region (1 in 2,500 children) and the lowest in the Eastern region (1 in 5,000 children). Affecting 1.5% of the Saudi Arabian pediatric population, GHD manifests as short stature, with 5,404 children under 5 years diagnosed. Global concerns surrounding an 83% mean adherence to once-daily growth hormone (GH) injections from 2018 to 2020 necessitate exploring alternative treatment modalities for pediatric GH deficiency, including weekly therapy.

Material and Method The introduction of Somapacitan, a pioneering weekly long-acting GH therapy, commenced in Saudi Arabia in January 2023, followed by the USA (April), Japan (June), and the European Union with Canada (July 2023). This presentation elucidates data from a single-center observational study involving 123 children diagnosed with growth hormone deficiency. Administration of once-weekly Somapacitan initiated in February 2023 forms the basis of our analysis.

Results Early observations following the adoption of weekly Somapacitan therapy reveal a substantial and statistically significant increase in mean growth velocity, reaching 8 cm/year. Furthermore, a noteworthy reduction in injection frequency underscores the potential for enhanced treatment adherence. Monitoring of serum insulin-like growth factor 1 (IGF-1) levels demonstrated a controlled elevation within the normal range, affirming the therapeutic efficacy of Somapacitan.

Conclusions Preliminary findings underscore a promising enhancement in growth parameters, coupled with a reduced injection burden and a commendable safety profile. The introduction of this novel long-acting GH therapy signifies a pivotal advancement in the therapeutic landscape of childhood GHD, offering a regimen conducive to heightened treatment adherence and improved clinical outcomes. Prospective research endeavors, encompassing extended follow-up durations, are imperative to corroborate and expand upon the auspicious implications emanating from this initial exploration. This study contributes valuable insights to the international discourse on pediatric GHD treatment modalities.

  • Growth hormone
  • Long-acting
  • children
  • clinical
  • outcome

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.